Shashi Amur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shashi Amur has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Hong Fang
ICF International at FDA's National Center for Toxicological Research, 3900 NCTR Rd, Jefferson, AR 72079, USA
2 shared publications Sarmistha Sanyal
Immediate Office, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA
2 shared publications- Weida Tong
Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food & Drug Administration, Jefferson, AR 72079, USA
2 shared publications Aliza Thompson
Division of Cardiovascular and Renal Products, Office of Drug Evaluation I, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA
1 shared publicationAloka G Chakravarty
Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation & Research, US Food & Drug Administration, Silver Spring, MD 20993-0002, USA
1 shared publicationAmeeta Parekh
1 shared publication
Latest Publications
- 25 November 2020
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 109  (3) , 569-572
FDA Experience With Regulation of Naloxone Products to Address the Opioid Crisis and Opportunities for Leveraging Scientific Engagement
- 25 November 2020
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 109  (3) , 569-572
FDA Experience With Regulation of Naloxone Products to Address the Opioid Crisis and Opportunities for Leveraging Scientific Engagement
- 15 May 2018
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 104  (6) , 1175-1181
Evaluating the Use of KIMâ1 in Drug Development and Research Following FDA Qualification
The Biomarker Qualification Program was established at the Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) to expedite the integration of promising biomarkers across multiple drug development programs. The first set of biomarkers qualified in 2008 consisted of seven nonclinical safety biomarkers for the detection of acute drugâinduced nephrotoxicity in rats, and included urinary kidney injury moleculeâ1 (KIMâ1). This article discusses the use of KIMâ1 in drug development and research before and after CDER's qualification of KIMâ1. Use was determined by analyzing relevant documents identified by keyword searches using three databases: 1) an FDA internal database, Document Archiving, Reporting, and Regulatory Tracking System (DARRTS); 2) ClinicalTrials.gov; and 3) PubMed. The results indicate increased use of KIMâ1 as a biomarker for detection of kidney injury in drug development programs reviewed by CDER, as well as in research following qualification.
- 15 May 2018
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 104  (6) , 1175-1181
Evaluating the Use of KIMâ1 in Drug Development and Research Following FDA Qualification
The Biomarker Qualification Program was established at the Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) to expedite the integration of promising biomarkers across multiple drug development programs. The first set of biomarkers qualified in 2008 consisted of seven nonclinical safety biomarkers for the detection of acute drugâinduced nephrotoxicity in rats, and included urinary kidney injury moleculeâ1 (KIMâ1). This article discusses the use of KIMâ1 in drug development and research before and after CDER's qualification of KIMâ1. Use was determined by analyzing relevant documents identified by keyword searches using three databases: 1) an FDA internal database, Document Archiving, Reporting, and Regulatory Tracking System (DARRTS); 2) ClinicalTrials.gov; and 3) PubMed. The results indicate increased use of KIMâ1 as a biomarker for detection of kidney injury in drug development programs reviewed by CDER, as well as in research following qualification.
- 3 November 2015
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 9  (11) , 1095-1105
Building a Roadmap to Biomarker Qualification: Challenges and Opportunities
The traditional route for regulatory acceptance of biomarkers in drug development is through submission of biomarker data in drug approval submissions in the context of a single drug development program. The US FDA's Critical Path Initiative called for establishment of a biomarker qualification process to enable progress in the drug development paradigm. In response to this, the Center for Drug Evaluation and Research (CDER) established a Biomarker Qualification Program (BQP) to qualify a biomarker for a specific context of use (COU). The qualified biomarker can then be used in multiple drug development programs for this COU without re-review. Here, we describe some of the features of the BQP and two new initiatives that have the potential to aid biomarker development through early interactions with the FDA. Finally, we discuss some of the feedback the FDA has received from submitters and the BQP's actions to strengthen the program.
- 3 November 2015
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 9  (11) , 1095-1105
Building a Roadmap to Biomarker Qualification: Challenges and Opportunities
The traditional route for regulatory acceptance of biomarkers in drug development is through submission of biomarker data in drug approval submissions in the context of a single drug development program. The US FDA's Critical Path Initiative called for establishment of a biomarker qualification process to enable progress in the drug development paradigm. In response to this, the Center for Drug Evaluation and Research (CDER) established a Biomarker Qualification Program (BQP) to qualify a biomarker for a specific context of use (COU). The qualified biomarker can then be used in multiple drug development programs for this COU without re-review. Here, we describe some of the features of the BQP and two new initiatives that have the potential to aid biomarker development through early interactions with the FDA. Finally, we discuss some of the feedback the FDA has received from submitters and the BQP's actions to strengthen the program.
- 6 June 2015
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 98  (1) , 34-46
Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization
The discovery, development, and use of biomarkers for a variety of drug development purposes are areas of tremendous interest and need. Biomarkers can become accepted for use through submission of biomarker data during the drug approval process. Another emerging pathway for acceptance of biomarkers is via the biomarker qualification program developed by the Center for Drug Evaluation and Research (CDER, US Food and Drug Administration). Evidentiary standards are needed to develop and evaluate various types of biomarkers for their intended use and multiple stakeholders, including academia, industry, government, and consortia must work together to help develop this evidence. The article describes various types of biomarkers that can be useful in drug development and evidentiary considerations that are important for qualification. A path forward for coordinating efforts to identify and explore needed biomarkers is proposed for consideration.
- 6 June 2015
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 98  (1) , 34-46
Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization
The discovery, development, and use of biomarkers for a variety of drug development purposes are areas of tremendous interest and need. Biomarkers can become accepted for use through submission of biomarker data during the drug approval process. Another emerging pathway for acceptance of biomarkers is via the biomarker qualification program developed by the Center for Drug Evaluation and Research (CDER, US Food and Drug Administration). Evidentiary standards are needed to develop and evaluate various types of biomarkers for their intended use and multiple stakeholders, including academia, industry, government, and consortia must work together to help develop this evidence. The article describes various types of biomarkers that can be useful in drug development and evidentiary considerations that are important for qualification. A path forward for coordinating efforts to identify and explore needed biomarkers is proposed for consideration.
- 1 May 2012
- Published by Elsevier in Journal of Autoimmunity
- Vol. 38  (2-3) , J254-J265
Sex differences and genomics in autoimmune diseases
- 1 May 2012
- Published by Elsevier in Journal of Autoimmunity
- Vol. 38  (2-3) , J254-J265
Sex differences and genomics in autoimmune diseases
- Open Access
- 30 May 2011
- Published by Springer Nature in BMC Medicine
- Vol. 9  (1) , 65
Meta-analysis of microarray data using a pathway-based approach identifies a 37-gene expression signature for systemic lupus erythematosus in human peripheral blood mononuclear cells
Background: A number of publications have reported the use of microarray technology to identify gene expression signatures to infer mechanisms and pathways associated with systemic lupus erythematosus (SLE) in human peripheral blood mononuclear cells. However, meta-analysis approaches with microarray data have not been well-explored in SLE. Methods: In this study, a pathway-based meta-analysis was applied to four independent gene expression oligonucleotide microarray data sets to identify gene expression signatures for SLE, and these data sets were confirmed by a fifth independent data set. Results: Differentially expressed genes (DEGs) were identified in each data set by comparing expression microarray data from control samples and SLE samples. Using Ingenuity Pathway Analysis software, pathways associated with the DEGs were identified in each of the four data sets. Using the leave one data set out pathway-based meta-analysis approach, a 37-gene metasignature was identified. This SLE metasignature clearly distinguished SLE patients from controls as observed by unsupervised learning methods. The final confirmation of the metasignature was achieved by applying the metasignature to a fifth independent data set. Conclusions: The novel pathway-based meta-analysis approach proved to be a useful technique for grouping disparate microarray data sets. This technique allowed for validated conclusions to be drawn across four different data sets and confirmed by an independent fifth data set. The metasignature and pathways identified by using this approach may serve as a source for identifying therapeutic targets for SLE and may possibly be used for diagnostic and monitoring purposes. Moreover, the meta-analysis approach provides a simple, intuitive solution for combining disparate microarray data sets to identify a strong metasignature. Please see Research Highlight: http://genomemedicine.com/content/3/5/30
- 30 May 2011
- Published by Springer Nature in BMC Medicine
- Vol. 9  (1) , 65
Open AccessMeta-analysis of microarray data using a pathway-based approach identifies a 37-gene expression signature for systemic lupus erythematosus in human peripheral blood mononuclear cells
Background: A number of publications have reported the use of microarray technology to identify gene expression signatures to infer mechanisms and pathways associated with systemic lupus erythematosus (SLE) in human peripheral blood mononuclear cells. However, meta-analysis approaches with microarray data have not been well-explored in SLE. Methods: In this study, a pathway-based meta-analysis was applied to four independent gene expression oligonucleotide microarray data sets to identify gene expression signatures for SLE, and these data sets were confirmed by a fifth independent data set. Results: Differentially expressed genes (DEGs) were identified in each data set by comparing expression microarray data from control samples and SLE samples. Using Ingenuity Pathway Analysis software, pathways associated with the DEGs were identified in each of the four data sets. Using the leave one data set out pathway-based meta-analysis approach, a 37-gene metasignature was identified. This SLE metasignature clearly distinguished SLE patients from controls as observed by unsupervised learning methods. The final confirmation of the metasignature was achieved by applying the metasignature to a fifth independent data set. Conclusions: The novel pathway-based meta-analysis approach proved to be a useful technique for grouping disparate microarray data sets. This technique allowed for validated conclusions to be drawn across four different data sets and confirmed by an independent fifth data set. The metasignature and pathways identified by using this approach may serve as a source for identifying therapeutic targets for SLE and may possibly be used for diagnostic and monitoring purposes. Moreover, the meta-analysis approach provides a simple, intuitive solution for combining disparate microarray data sets to identify a strong metasignature. Please see Research Highlight: http://genomemedicine.com/content/3/5/30
- 1 November 2010
- Published by Taylor & Francis in Personalized Medicine
- Vol. 7  (6) , 633-642
PHarmacogenomics and Adverse Drug Reactions
Adverse drug reactions (ADRs) observed during drug development have been the cause for discontinuing development of many drugs. In addition, serious but rare ADRs observed after marketing have led to withdrawal of some drugs. A priori identification of individuals at risk of developing ADRs for a given drug will help develop strategies to reduce the risk for ADRs in these patients. US FDA initiatives and efforts at reducing ADRs to make drugs safer are described, including updating of drug labels to include genomic information intended to reduce ADRs. Pharmacogenomics can also be harnessed to identify individuals at risk of developing serious ADRs and to treat these individuals with alternative therapy, thus converting ADRs that are traditionally considered unavoidable to avoidable ADRs.
- 1 November 2010
- Published by Taylor & Francis in Personalized Medicine
- Vol. 7  (6) , 633-642
PHarmacogenomics and Adverse Drug Reactions
Adverse drug reactions (ADRs) observed during drug development have been the cause for discontinuing development of many drugs. In addition, serious but rare ADRs observed after marketing have led to withdrawal of some drugs. A priori identification of individuals at risk of developing ADRs for a given drug will help develop strategies to reduce the risk for ADRs in these patients. US FDA initiatives and efforts at reducing ADRs to make drugs safer are described, including updating of drug labels to include genomic information intended to reduce ADRs. Pharmacogenomics can also be harnessed to identify individuals at risk of developing serious ADRs and to treat these individuals with alternative therapy, thus converting ADRs that are traditionally considered unavoidable to avoidable ADRs.
- Open Access
- 12 August 2008
- Published by Springer Nature in BMC Bioinformatics
- Vol. 9  (S9) , S10
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies
Reproducibility is a fundamental requirement in scientific experiments. Some recent publications have claimed that microarrays are unreliable because lists of differentially expressed genes (DEGs) are not reproducible in similar experiments. Meanwhile, new statistical methods for identifying DEGs continue to appear in the scientific literature. The resultant variety of existing and emerging methods exacerbates confusion and continuing debate in the microarray community on the appropriate choice of methods for identifying reliable DEG lists.
- 12 August 2008
- Published by Springer Nature in BMC Bioinformatics
- Vol. 9  (S9) , S10
Open AccessThe balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies
Reproducibility is a fundamental requirement in scientific experiments. Some recent publications have claimed that microarrays are unreliable because lists of differentially expressed genes (DEGs) are not reproducible in similar experiments. Meanwhile, new statistical methods for identifying DEGs continue to appear in the scientific literature. The resultant variety of existing and emerging methods exacerbates confusion and continuing debate in the microarray community on the appropriate choice of methods for identifying reliable DEG lists.